Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CNTB NASDAQ:FGEN NASDAQ:MCRB NASDAQ:SKYE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTBConnect Biopharma$2.20+7.8%$1.31$0.51▼$2.86$113.35M-0.09287,638 shs80,045 shsFGENFibroGen$6.91-0.3%$6.80$4.50▼$21.94$28.01M0.7640,226 shs12,584 shsMCRBSeres Therapeutics$14.28-3.4%$10.61$6.53▼$26.40$129.07M2.9148,979 shs147,475 shsSKYESkye Bioscience$3.79+4.4%$3.34$1.14▼$7.47$112.44M2.21434,296 shs214,593 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTBConnect Biopharma+7.84%+25.71%+93.83%+175.00%+100.00%FGENFibroGen-0.29%-3.76%+21.44%-15.21%-39.29%MCRBSeres Therapeutics-3.38%+17.53%+25.76%+72.26%-44.22%SKYESkye Bioscience+4.41%+4.99%-17.16%+108.24%-31.96%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCNTBConnect Biopharma2.9979 of 5 stars3.83.00.00.03.12.50.0FGENFibroGen4.4227 of 5 stars3.35.00.04.71.13.30.6MCRBSeres Therapeutics2.9683 of 5 stars2.91.00.04.61.70.80.0SKYESkye Bioscience1.1867 of 5 stars3.52.00.00.00.60.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNTBConnect Biopharma 3.50Strong Buy$7.00218.18% UpsideFGENFibroGen 2.50Moderate Buy$250.003,517.95% UpsideMCRBSeres Therapeutics 1.75Reduce$73.67415.87% UpsideSKYESkye Bioscience 3.00Buy$16.60337.99% UpsideCurrent Analyst Ratings BreakdownLatest FGEN, SKYE, MCRB, and CNTB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/22/2025CNTBConnect BiopharmaNorthland CapmkSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/24/2025SKYESkye BioscienceJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$15.006/12/2025CNTBConnect BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$7.005/20/2025SKYESkye BioscienceWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform5/13/2025FGENFibroGenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$250.00 ➝ $250.005/8/2025MCRBSeres TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$1.25 ➝ $6.00(Data available from 8/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNTBConnect Biopharma$26.03M4.70N/AN/A$1.67 per share1.32FGENFibroGen$29.62M0.94N/AN/A($50.89) per share-0.14MCRBSeres Therapeutics$126.32M0.99N/AN/A$1.61 per share8.87SKYESkye BioscienceN/AN/AN/AN/A$2.25 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNTBConnect Biopharma-$15.63MN/A0.00N/AN/AN/AN/AN/A9/5/2025 (Estimated)FGENFibroGen-$47.58M-$2.50N/AN/AN/A-9.73%N/A-24.77%N/AMCRBSeres Therapeutics$140K-$4.60N/AN/AN/AN/A-41,084.76%-55.87%8/6/2025 (Estimated)SKYESkye Bioscience-$26.57M-$0.82N/AN/AN/AN/A-53.92%-48.58%N/ALatest FGEN, SKYE, MCRB, and CNTB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025MCRBSeres Therapeutics-$2.72N/AN/AN/AN/AN/A5/15/2025Q1 2025CNTBConnect Biopharma-$0.26-$0.19+$0.07-$0.19N/AN/A5/12/2025Q1 2025FGENFibroGen$0.75-$4.00-$4.75$0.05$2.00 million$2.70 million5/8/2025Q1 2025SKYESkye Bioscience-$0.31-$0.28+$0.03-$0.28N/AN/A5/7/2025Q1 2025MCRBSeres Therapeutics-$0.67-$2.24-$1.57$3.75$10.00 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCNTBConnect BiopharmaN/AN/AN/AN/AN/AFGENFibroGenN/AN/AN/AN/AN/AMCRBSeres TherapeuticsN/AN/AN/AN/AN/ASKYESkye BioscienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNTBConnect Biopharma0.0110.2510.25FGENFibroGenN/A2.021.98MCRBSeres TherapeuticsN/A2.112.11SKYESkye BioscienceN/A11.8511.85Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNTBConnect Biopharma58.72%FGENFibroGen72.71%MCRBSeres Therapeutics59.34%SKYESkye Bioscience21.09%Insider OwnershipCompanyInsider OwnershipCNTBConnect Biopharma22.60%FGENFibroGen1.98%MCRBSeres Therapeutics4.70%SKYESkye Bioscience3.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNTBConnect Biopharma11055.56 million43.00 millionOptionableFGENFibroGen5704.04 million3.96 millionOptionableMCRBSeres Therapeutics3308.73 million8.32 millionOptionableSKYESkye Bioscience1130.98 million30.05 millionOptionableFGEN, SKYE, MCRB, and CNTB HeadlinesRecent News About These CompaniesWe Think Skye Bioscience (NASDAQ:SKYE) Needs To Drive Business Growth Carefully51 minutes ago | finance.yahoo.comSkye Bioscience, Inc. (NASDAQ:SKYE) Receives $16.60 Average PT from AnalystsJuly 31, 2025 | americanbankingnews.comSkye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025July 30, 2025 | globenewswire.comSkye Bioscience, Inc. (NASDAQ:SKYE) Given Average Recommendation of "Buy" by AnalystsJuly 28, 2025 | marketbeat.comSkye Bioscience (NASDAQ:SKYE) Shares Down 8% - What's Next?July 25, 2025 | marketbeat.comSKYE Stock Price Quote | MorningstarJuly 11, 2025 | morningstar.comMSkye Bioscience, Inc. (SKYE) - Yahoo FinanceJuly 9, 2025 | finance.yahoo.comSkye Bioscience Highlights Nimacimab’s Promise in Obesity Treatment, Anticipates Phase 2a DataJuly 6, 2025 | msn.comPositive week for Skye Bioscience, Inc. (NASDAQ:SKYE) institutional investors who lost 53% over the past yearJune 25, 2025 | finance.yahoo.comSkye Bioscience Shares Nimacimab "Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th ...June 24, 2025 | manilatimes.netMSkye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes ... - MorningstarJune 24, 2025 | morningstar.comMSkye Bioscience Launches "Anatomy of Progress" Video Series on Nimacimab Development for Obesity Treatment - NasdaqJune 24, 2025 | nasdaq.comSkye Bioscience Launches "Anatomy of Progress" Video Series on Nimacimab Development for Obesity TreatmentJune 23, 2025 | quiverquant.comQSkye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th Scientific SessionsJune 23, 2025 | globenewswire.comSkye confirms phase 2 data on nimacimab for obesity expected later this yearJune 19, 2025 | msn.comSkye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association’s 85th Scientific SessionsJune 17, 2025 | finance.yahoo.comSkye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association's 85th Scientific SessionsJune 17, 2025 | globenewswire.com3 Stocks Targeting Weight Loss Market With Cannabinoid-Based TherapiesMay 23, 2025 | zacks.comSkye Bioscience to Participate in Upcoming Investment ConferencesMay 22, 2025 | globenewswire.comSkye And Arecor Partner To Develop Advanced Nimacimab Formulation For Obesity TreatmentMay 21, 2025 | nasdaq.comQ&A: Next wave of obesity drugs may ‘afford a lot of advantages’May 20, 2025 | healio.comHNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFGEN, SKYE, MCRB, and CNTB Company DescriptionsConnect Biopharma NASDAQ:CNTB$2.20 +0.16 (+7.84%) Closing price 08/5/2025 04:00 PM EasternExtended Trading$2.15 -0.05 (-2.27%) As of 08/5/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.FibroGen NASDAQ:FGEN$6.91 -0.02 (-0.29%) Closing price 08/5/2025 04:00 PM EasternExtended Trading$6.94 +0.04 (+0.51%) As of 08/5/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.Seres Therapeutics NASDAQ:MCRB$14.28 -0.50 (-3.38%) Closing price 08/5/2025 04:00 PM EasternExtended Trading$14.60 +0.32 (+2.23%) As of 08/5/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.Skye Bioscience NASDAQ:SKYE$3.79 +0.16 (+4.41%) Closing price 08/5/2025 04:00 PM EasternExtended Trading$3.75 -0.04 (-0.95%) As of 08/5/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Stock Soars After Blowout Earnings Report Vertical Aerospace's New Deal and Earnings De-Risk Production Zebra Technologies: Riding the Automation Wave to Profits Stop Overlooking Qualcomm—Here’s What the Market’s Missing Amazon Enters Correction Zone: Time to Panic or Be Brave? Figma's Wild IPO Ride: Is the Stock's Premium Price Justified? Applied Digital: Why a Surge in Bullish Bets Signals a New Era META Gets Huge Upgrades: How High Analysts Think Shares Could Go Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
